Author/Authors :
Bayat, Ali-Ahmad Monoclonal Antibody Research Center - Avicenna Research Institute - ACECR - Tehran, Iran , Sadeghi, Niloufar Monoclonal Antibody Research Center - Avicenna Research Institute - ACECR - Tehran, Iran , Fatemi, Ramina Monoclonal Antibody Research Center - Avicenna Research Institute - ACECR - Tehran, Iran , Nowroozi, Mohammad Reza Uro-Oncology Research Center - Tehran University of Medical Sciences - Tehran, Iran , Ohadian Moghadam, Solmaz Uro-Oncology Research Center - Tehran University of Medical Sciences - Tehran, Iran , Borzuee, Mohadeseh Uro-Oncology Research Center - Tehran University of Medical Sciences - Tehran, Iran , Radmanesh, Amin Legal Medicine Research Center - Legal Medicine Organization - Tehran, Iran , Khodadoost, Mahmood Faculty of Traditional Medicine - Traditional Medicine and Materia Medica Research Center - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Sarrafzadeh, Ali Reza Department of Pathology - Khatam Al Anbia Hospital - Tehran, Iran , Zarei, Omid Cellular and Molecular Research Center - Research Institute for Health Development - Kurdistan University of Medical Sciences - Sanandaj, Iran , Rabbani, Hodjattallah Monoclonal Antibody Research Center - Avicenna Research Institute - ACECR - Tehran, Iran
Abstract :
Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) is one of the
promising cell surface antigens for targeting cancer cells. The aim of this study was to
evaluate ROR1 cell surface expression in bladder cancer cells using a murine anti-ROR1
monoclonal antibody (mAb) called 5F1-B10 as well as investigate its potential in
apoptosis induction.
Methods: Expression of ROR1 in two human bladder cell lines, 5637 and EJ138, as well
as a non-cancerous human cell line, Human Fetal Foreskin Fibroblast (HFFF), was
examined by flow cytometry and immunocytochemistry. Immunohistochemical staining
of cancer and normal bladder tissues was also performed.
Results: The flow cytometry results showed that 5F1-B10 mAb could recognize ROR1
molecules in 86.1% and 45.6% of 5637 and EJ138 cells, respectively. The expression level
of ROR1 was 5.49% in HFFF cells. The immunocytochemistry and immunohistochemistry
staining results also confirmed the presence of ROR1 on the surface of both bladder
cancer cells and tissues, respectively. The obtained data from apoptosis assay demonstrated
that 5F1-B10 mAb could induce apoptosis in both 5637 and EJ138 cell lines.
Conclusion: Taken together, our finding indicates the role of ROR1 in bladder cancer
cell survival and suggests this receptor might be a promising target for developing
novel therapeutic agents against bladder carcinoma.
Keywords :
ROR1 protein , Bladder cancer , Monoclonal antibody , Flow cytometry